Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated via claimed linking group – bond – chelating agent,...
Reexamination Certificate
1998-05-01
2002-05-28
Saunders, David (Department: 1644)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated via claimed linking group, bond, chelating agent,...
C424S134100, C424S141100, C424S178100, C424S183100, C424S192100, C424S193100, C514S012200, C514S04400A, C530S387300, C530S391700
Reexamination Certificate
active
06395276
ABSTRACT:
FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not applicable.
BACKGROUND OF THE INVENTION
Toxic enzymes from plants and bacteria such as ricin, diphtheria toxin and Pseudomonas toxin have been coupled to antibodies or receptor binding ligands to generate cell-type-specific-killing reagents (Youle, et al.,
Proc. Nat'l Acad. Sci. USA
77:5483 (1980); Gilliland, et al.,
Proc. Nat'l Acad. Sci. USA
77:4539 (1980); Krolick, et al.,
Proc. Nat'l Acad. Sci. USA
77:5419 (1980)). Regardless of the fact that the cell-recognition moiety is not always an antibody, these directed toxins are generally known as immunotoxins. These hybrid proteins kill cells which express the receptor or cell surface marker that the antibody or ligand portion of the molecule recognizes.
Under appropriate conditions, depending on the particular receptor or cell surface marker, the toxin enters the cytosol, inactivates the protein synthesis machinery and causes death of the target cell. Immunotoxins, which have been shown to be highly cytotoxic to cancer cells growing in cell culture and in animal models, demonstrate the potential of these reagents to treat blood and lymph borne malignancies which, because of their dissemination are not treatable by traditional surgical techniques, as well as solid tumors in restricted compartments such as the intraperitoneal cavity (reviewed in Griffin, et al., IMMUNOTOXINS, p 433, Boston/Dordrecht/Lancaster, Kluwer Academic Publishers, (1988); Vitetta, et al.,
Science
238:1098 (1987); Fitzgerald, et al.,
J. Nat'l Cancer Inst
. 81:1455 (1989)). Traditional chemotherapies, while being effective in the treatment of some cancerous conditions, exhibit undesired side effects due to the systemic toxicity of the chemotherapeutic compounds.
An ideal candidate for cancer therapy, therefore, would be an immunotoxin that would selectively be cytotoxic to cancer cells yet remain harmless to non-cancerous cells of the patient. Utilization of this type of anti-tumor therapy, however, has been stymied by the development of immune responses in patients to foreign proteins which comprise the immunotoxins. Immune responses against murine monoclonal antibodies (Sawler, et al.,
J. Immunol
. 135:1530 (1985); Schroff, et al.,
Cancer Res
. 45:879 (1985)) and anti-toxin antibodies have been detected in both animals and humans treated with immunotoxins (Rybak, et al.,
Immunol. and Allergy Clinics of North America
11(2):359 (1991); Harkonen, et al.,
Cancer Res
. 47:1377 (1987); Hertler, A. in IMMUNOTOXINS p. 475, Kluwer Academic Publishers, Boston/Dordrecht/Lancaster (1988)). Advances in humanization techniques have alleviated some of the immunogenicity associated with the antibody portion of immunotoxins (Bird, et al.,
Science
242:423 (1988); Huston, et al.,
Proc. Nat'l Acad. Sci. USA
85:5879 (1988); Ward, et al.,
Nature
341:544 (1989); and Jones, et al.,
Nature
314:522 (1986)). However, no solution has been found to counter the immunogenicity of the toxic moiety other than immunosuppression of the patients (Khazaeli, et al.,
Proceedings of AACR
29:418 (1988)). Thus, there has been a continuing need for methods and compositions that would reduce the immunogenicity of the toxic moiety of immunotoxins yet retain the ability to selectively kill cells having a given surface marker.
B-cell lymphomas fall under the generic rubric of non-Hodgkin's lymphomas and can either be a disseminated or a solid tumor within the lymph system. Radiolabeled humanized murine antibodies which have been raised against CD22 (LymphoCide™), a surface marker on malignant B cells, are currently in clinical trials as a treatment for B-cell lymphomas (Immunomedics, Inc., Press Release, http://www.immunomedic.com/ theral.html). See also, Amlot, et al.,
Blood
82:2624-2633 (1993); Sausville, et al.,
Blood
85:3457-3465 (1995); Grossbard, et al.,
Blood
81:2263-2271 (1993); Grossbard, et al.,
Clin. Oncol
. 11:726-737 (1993). To date, some antitumor responses have been noted but immunotoxin-mediated toxicity to normal tissue often prevented dosing at therapeutic levels. In addition to CD22, several B-cell-specific antigens such as CD 19 and CD40 have been targeted by immunotoxins made with plant toxins such as ricin A-chain and bacterial toxins, such as Pseudomonas exotoxin A (PE). Uckun, et al.,
Blood
79:2201-2214 (1992); Ghetie, et al.,
Cancer Res
. 51:5876-5880 (1991); Francisco, et al.,
Cancer Res
. 55:3099-3104 (1995).
The cytotoxicity of RNase A toward tumor cells is well documented from studies performed in the 1960s and 1970s. Early work is reviewed in Roth,
Cancer Res
. 23:657 (1963). The relevance of these early studies has been sustained by the discovery that an anti-tumor protein from oocytes of
Rana pipiens
is homologous to bovine pancreatic RNase A (Ardelt, et al.,
J Biol. Chem
. 256:245 (1991)). P-30 protein (and referred to herein as the onc protein) was isolated from extracts of
Rana pipiens
early embryos based upon anti-proliferative/cytotoxic effects toward cancer cells in vitro (Darzynkiewicz, et al.,
Cell Tissue Kinet
. 21:169 (1988); Mikulski, et al.,
Cell Tissue Kinet
. 23:237 (1990)) and in animal models (Mikulski, et al.,
J. Nat l. Cancer Inst
. 82:151 (1990)). Phase III human clinical trials of the onc protein in patients with a variety of solid tumors are currently in progress.
SUMMARY OF THE INVENTION
The present invention relates to immunotoxins, that are useful for killing malignant B cells and other malignant cells and are directed to a surface marker on B cells and the nucleic acid constructs encoding the immunotoxins. These reagents comprise a toxic moiety that is derived from a
Rana pipiens
protein having ribonucleolytic activity linked to an antibody capable of specific binding with a chosen tumor cell.
We have found that these particular immunotoxins had highly surprising properties as they were up to 2000fold more active against malignant B cells than their human RNase counterparts or than the toxin itself. Further, as will be described in more detail below, their use when administered in vivo against disseminated tumors, resulted in dramatically lowered side effects. These highly effective, but apparently non-toxic, immunotoxins directed against such ubiquitous diseases as B cell lymphomas present a new and exciting therapeutic option for patients suffering from such diseases.
It is an object of the present invention to provide cytotoxic RNase (onc protein) immunotoxins that selectively kill cells having a given surface marker. These immunotoxins are minimally immunogenic and generate less systemic toxicity than presently known immunotoxins. In particular, it is an object of the present invention to provide direct immunotoxins comprising protein fragments with ribonucleolytic activity linked to humanized antibodies that recognize specific markers on tumor cells.
In another embodiment, the present invention relates to a pharmaceutical composition comprising an immunotoxin of the present invention and a pharmaceutically acceptable carrier.
In a further embodiment, the present invention relates to a method selectively killing cells. The method comprises contacting the tumor cells to be killed with a selective immunotoxin of the present invention under conditions such that the monoclonal antibody binds to a surface marker on the tumor cell thereby causing the toxic onc protein to kill the cell.
Various other objects and advantages of the present invention will be apparent from the following description of the invention.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5559212 (1996-09-01), Wojciech
patent: 5728805 (1998-03-01), Wojciech
patent: 5840840 (1998-11-01), Rybak et al.
patent: 5995073 (1999-09-01), Rybak et al.
patent: 6083477 (2000-07-01), Goldenberg
patent: 0 173 494 (1985-07-01), None
patent: WO 87/02671 (1986-10-01), None
patent: WO 88/09344 (1988-05-01), None
patent: WO 97/02588 (1996-06-01), None
patent: PCT/US98/05453 (1998-03-01), None
Rybak et al. PNAS, 89:3165-3169, 1992.*
De Prisco, et al., A Ribonuclease from
Goldenberg David M.
Newton Dianne L.
Rybak Susanna M.
DeCloux Amy
Immunomedics Inc.
Saunders David
LandOfFree
Immunotoxins directed against malignant cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotoxins directed against malignant cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotoxins directed against malignant cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2818592